NCT04979572View on ClinicalTrials.gov

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

January 26, 2022

Study Completion Date

January 26, 2022

Conditions
Healthy Adult Subjects
Interventions
DRUG

TS-172

"* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner"

DRUG

Placebo

"* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner"

Trial Locations (1)

Unknown

Taisho Pharmaceutical Co., Ltd selected site, Toshima-ku

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04979572 - A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses) | Biotech Hunter | Biotech Hunter